Additional Description:
3DFying develops and supplies semisolid-extrusion (SSE) 3D printing systems designed for pharmaceutical formulation development, personalized medicines, and advanced drug-delivery research. The platform enables controlled deposition of semisolid pharmaceutical formulations to produce dose-flexible tablets, oral films, gummies, polypills, and other customized dosage forms without relying on conventional high-temperature filament processing.
For pharmaceutical companies and research institutions, 3DFying offers configurable SSE 3D printer systems along with application development, formulation optimization, printing-parameter development, rapid prototyping, and process-support services. The technology can help shorten early formulation-development cycles, enable small-batch and patient-specific dose exploration, and support preclinical and clinical research requiring customized strengths, geometries, release profiles, or multidrug combinations.
3DFying also provides contract R&D services covering formulation feasibility, material selection, printability assessment, design of dosage-form geometry, process optimization, Quality-by-Design studies, and development of research-ready printing workflows. The platform is being developed as a scalable pharmaceutical manufacturing and prototyping solution that bridges laboratory formulation research with future decentralized and personalized medicine applications.
Leave your rating & comment